Königsbrügge O, Posch F, Antlanger M, et al. Prevalence of atrial fibrillation and antithrombotic therapy in hemodialysis patients: cross‐sectional results of the Vienna InVestigation of AtriaL Fibrillation and Thromboembolism in Patients on HemoDIaLysis (VIVALDI). PLoS ONE. 2017;12:e0169400.
 Ball J, Carrington MJ, McMurray JJV, Stewart S. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013;167:1807–24.
 Saran R, Robinson B, Abbott KC, et al. US Renal Data System 2016 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69(3S1):A7–A8.
 Goldstein BA, Arce CM, Hlatky MA, Turakhia M, Setoguchi S, Winkelmayer WC. Trends in the incidence of atrial fibrillation in older patients initiating dialysis in the United States. Circulation. 2012;126:2293–2301.
 R. H. Falk. Etiology and complications of atrial fibrillation: insights from pathology studies. Am J Cardiol, 82 (8A) (1998), pp. 10N–17N
 Buiten MS, de Bie MK, Rotmans JI, Gabreëls BA, van Dorp W, Wolterbeek R, et al. The dialysis procedure as a trigger for atrial fibrillation: new insights in the development of atrial fibrillation in dialysis patients. Heart. 2014;100:685–90.
 Genovesi S, Vincenti A, Rossi E, Pogliani D, Acquistapace I, Stella A, et al. Atrial fibrillation and morbidity and mortality in a cohort of long‐term hemodialysis patients. Am J Kidney Dis. 2008;51:255–62.
 Herzog CA, Asinger RW, Berger AK, et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int. 2011;80(6):572–586.
 January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm. Heart Rhythm. 2019;16(8):e66-e93.
 Mitsuma W, Matsubara T, Hatada K, et al. Atrial fibrillation had less impact on the risk of ischemic stroke in non-anticoagulated patients undergoing hemodialysis: insight from the RAKUEN study. Intern Med. 2018;57(16):2295–2300.
 Tanaka A, Inaguma D, Shinjo H, et al. Presence of Atrial Fibrillation at the Time of Dialysis Initiation Is Associated with Mortality and Cardiovascular Events. Nephron 2016;132:86–92
 Leong DP, Eikelboom JW, Healey JS, Connolly SJ. Atrial fibrillation is associated with increased mortality: causation or association? Eur Heart J. 2013;34(14):1027–1030.
 Odutayo A, Wong CX, Hsiao AJ, Hopewell S, Altman DG, Emdin CA. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: Systematic review and meta-analysis. BMJ. 2016:354–i4482.
 Kai B, Bogorad Y, Nguyen LN, et al. (2017). Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation. Heart Rhythm 14, 645–651.
 Shen JI, Montez‐Rath ME, Lenihan CR, Turakhia MP, Chang TI, Winkelmayer WC. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015;66:677–88.
 Wakasugi M, Kazama JJ, Tokumoto A, et al. (2013). Association between warfarin use and incidence of ischemic stroke in Japanese hemodialysis patients with chronic sustained atrial fibrillation: a prospective cohort study. Clin. Exp. Nephrol. 18, 662–669.
 Lee M, Saver JL, Hong K‐S, et al. Warfarin use and risk of stroke in patients with atrial fibrillation undergoing hemodialysis: a meta‐analysis. Medicine. 2016;95(6):e2741
 C. I. Coleman, R. Kreutz, N. A. Sood,et al. Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and severe kidney disease or undergoing hemodialysis.
Am J Med 2019 Sep;132(9):1078–1083.
 Siontis KC, Zhang X, Eckard A, et al. Outcomes associated with Apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation. 2018;138(15):1519–1529.